nodes	percent_of_prediction	percent_of_DWPC	metapath
Milnacipran—Hypertensive crisis—Capecitabine—esophageal cancer	0.036	0.036	CcSEcCtD
Milnacipran—Panic attack—Capecitabine—esophageal cancer	0.0268	0.0269	CcSEcCtD
Milnacipran—Night sweats—Capecitabine—esophageal cancer	0.0185	0.0185	CcSEcCtD
Milnacipran—Infection—Carboplatin—esophageal cancer	0.0164	0.0164	CcSEcCtD
Milnacipran—Supraventricular tachycardia—Capecitabine—esophageal cancer	0.0152	0.0153	CcSEcCtD
Milnacipran—Body temperature increased—Carboplatin—esophageal cancer	0.013	0.013	CcSEcCtD
Milnacipran—Contusion—Capecitabine—esophageal cancer	0.0114	0.0115	CcSEcCtD
Milnacipran—Proteinuria—Capecitabine—esophageal cancer	0.0114	0.0114	CcSEcCtD
Milnacipran—Chest discomfort—Capecitabine—esophageal cancer	0.0113	0.0113	CcSEcCtD
Milnacipran—Protein urine present—Capecitabine—esophageal cancer	0.0112	0.0112	CcSEcCtD
Milnacipran—Ventricular extrasystoles—Capecitabine—esophageal cancer	0.0111	0.0111	CcSEcCtD
Milnacipran—Gastrooesophageal reflux disease—Capecitabine—esophageal cancer	0.0111	0.0111	CcSEcCtD
Milnacipran—Renal failure acute—Cisplatin—esophageal cancer	0.0106	0.0107	CcSEcCtD
Milnacipran—Blood pressure increased—Capecitabine—esophageal cancer	0.00998	0.01	CcSEcCtD
Milnacipran—Hyponatraemia—Cisplatin—esophageal cancer	0.00987	0.00989	CcSEcCtD
Milnacipran—Irritability—Cisplatin—esophageal cancer	0.00938	0.0094	CcSEcCtD
Milnacipran—Dry eye—Capecitabine—esophageal cancer	0.00922	0.00924	CcSEcCtD
Milnacipran—Breast disorder—Cisplatin—esophageal cancer	0.00888	0.0089	CcSEcCtD
Milnacipran—Proteinuria—Methotrexate—esophageal cancer	0.00846	0.00847	CcSEcCtD
Milnacipran—Protein urine present—Methotrexate—esophageal cancer	0.00834	0.00836	CcSEcCtD
Milnacipran—Renal failure acute—Capecitabine—esophageal cancer	0.00785	0.00786	CcSEcCtD
Milnacipran—Libido decreased—Capecitabine—esophageal cancer	0.00782	0.00783	CcSEcCtD
Milnacipran—Hot flush—Capecitabine—esophageal cancer	0.00775	0.00776	CcSEcCtD
Milnacipran—Menopausal symptoms—Capecitabine—esophageal cancer	0.00768	0.00769	CcSEcCtD
Milnacipran—Thirst—Capecitabine—esophageal cancer	0.00762	0.00763	CcSEcCtD
Milnacipran—Hyponatraemia—Capecitabine—esophageal cancer	0.00728	0.00729	CcSEcCtD
Milnacipran—Cystitis noninfective—Methotrexate—esophageal cancer	0.00726	0.00727	CcSEcCtD
Milnacipran—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00719	0.0072	CcSEcCtD
Milnacipran—Cystitis—Methotrexate—esophageal cancer	0.00718	0.00719	CcSEcCtD
Milnacipran—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00717	0.00718	CcSEcCtD
Milnacipran—Migraine—Capecitabine—esophageal cancer	0.00713	0.00715	CcSEcCtD
Milnacipran—Irritability—Capecitabine—esophageal cancer	0.00692	0.00693	CcSEcCtD
Milnacipran—Urinary retention—Capecitabine—esophageal cancer	0.00689	0.0069	CcSEcCtD
Milnacipran—Bladder pain—Methotrexate—esophageal cancer	0.00672	0.00673	CcSEcCtD
Milnacipran—Urinary tract disorder—Cisplatin—esophageal cancer	0.00672	0.00673	CcSEcCtD
Milnacipran—Liver function test abnormal—Capecitabine—esophageal cancer	0.00669	0.0067	CcSEcCtD
Milnacipran—Connective tissue disorder—Cisplatin—esophageal cancer	0.00668	0.0067	CcSEcCtD
Milnacipran—Urethral disorder—Cisplatin—esophageal cancer	0.00667	0.00668	CcSEcCtD
Milnacipran—Dry skin—Capecitabine—esophageal cancer	0.00664	0.00666	CcSEcCtD
Milnacipran—Breast disorder—Capecitabine—esophageal cancer	0.00655	0.00656	CcSEcCtD
Milnacipran—Eye disorder—Cisplatin—esophageal cancer	0.00636	0.00637	CcSEcCtD
Milnacipran—Flushing—Cisplatin—esophageal cancer	0.00631	0.00632	CcSEcCtD
Milnacipran—Cardiac disorder—Cisplatin—esophageal cancer	0.00631	0.00632	CcSEcCtD
Milnacipran—Abdominal distension—Capecitabine—esophageal cancer	0.00631	0.00632	CcSEcCtD
Milnacipran—Mediastinal disorder—Cisplatin—esophageal cancer	0.00613	0.00614	CcSEcCtD
Milnacipran—Angina pectoris—Capecitabine—esophageal cancer	0.0061	0.00611	CcSEcCtD
Milnacipran—Malnutrition—Cisplatin—esophageal cancer	0.00592	0.00593	CcSEcCtD
Milnacipran—Dysuria—Capecitabine—esophageal cancer	0.00586	0.00587	CcSEcCtD
Milnacipran—Neutropenia—Capecitabine—esophageal cancer	0.00586	0.00587	CcSEcCtD
Milnacipran—Renal failure acute—Methotrexate—esophageal cancer	0.00584	0.00585	CcSEcCtD
Milnacipran—Flatulence—Cisplatin—esophageal cancer	0.00583	0.00585	CcSEcCtD
Milnacipran—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00582	0.00583	CcSEcCtD
Milnacipran—Weight decreased—Capecitabine—esophageal cancer	0.00567	0.00568	CcSEcCtD
Milnacipran—Vision blurred—Cisplatin—esophageal cancer	0.00558	0.00559	CcSEcCtD
Milnacipran—Tremor—Cisplatin—esophageal cancer	0.00555	0.00556	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00554	0.00555	CcSEcCtD
Milnacipran—Urinary tract infection—Capecitabine—esophageal cancer	0.00543	0.00544	CcSEcCtD
Milnacipran—Haematuria—Capecitabine—esophageal cancer	0.00533	0.00534	CcSEcCtD
Milnacipran—Leukopenia—Cisplatin—esophageal cancer	0.0053	0.00531	CcSEcCtD
Milnacipran—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00528	0.00529	CcSEcCtD
Milnacipran—Irritability—Methotrexate—esophageal cancer	0.00515	0.00516	CcSEcCtD
Milnacipran—Convulsion—Cisplatin—esophageal cancer	0.00513	0.00514	CcSEcCtD
Milnacipran—Anxiety—Cisplatin—esophageal cancer	0.00502	0.00503	CcSEcCtD
Milnacipran—Hepatitis—Capecitabine—esophageal cancer	0.00501	0.00502	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00501	0.00502	CcSEcCtD
Milnacipran—Hypoaesthesia—Capecitabine—esophageal cancer	0.00499	0.005	CcSEcCtD
Milnacipran—Liver function test abnormal—Methotrexate—esophageal cancer	0.00498	0.00499	CcSEcCtD
Milnacipran—Urinary tract disorder—Capecitabine—esophageal cancer	0.00495	0.00496	CcSEcCtD
Milnacipran—Oedema peripheral—Capecitabine—esophageal cancer	0.00494	0.00495	CcSEcCtD
Milnacipran—Connective tissue disorder—Capecitabine—esophageal cancer	0.00493	0.00494	CcSEcCtD
Milnacipran—Urethral disorder—Capecitabine—esophageal cancer	0.00491	0.00492	CcSEcCtD
Milnacipran—Breast disorder—Methotrexate—esophageal cancer	0.00488	0.00488	CcSEcCtD
Milnacipran—Infection—Cisplatin—esophageal cancer	0.0048	0.00481	CcSEcCtD
Milnacipran—Erythema multiforme—Capecitabine—esophageal cancer	0.00474	0.00475	CcSEcCtD
Milnacipran—Nervous system disorder—Cisplatin—esophageal cancer	0.00474	0.00475	CcSEcCtD
Milnacipran—Thrombocytopenia—Cisplatin—esophageal cancer	0.00473	0.00474	CcSEcCtD
Milnacipran—Tachycardia—Cisplatin—esophageal cancer	0.00472	0.00472	CcSEcCtD
Milnacipran—Skin disorder—Cisplatin—esophageal cancer	0.00469	0.0047	CcSEcCtD
Milnacipran—Eye disorder—Capecitabine—esophageal cancer	0.00469	0.00469	CcSEcCtD
Milnacipran—Hyperhidrosis—Cisplatin—esophageal cancer	0.00467	0.00468	CcSEcCtD
Milnacipran—Flushing—Capecitabine—esophageal cancer	0.00465	0.00466	CcSEcCtD
Milnacipran—Cardiac disorder—Capecitabine—esophageal cancer	0.00465	0.00466	CcSEcCtD
Milnacipran—Anorexia—Cisplatin—esophageal cancer	0.00461	0.00461	CcSEcCtD
Milnacipran—Angiopathy—Capecitabine—esophageal cancer	0.00455	0.00456	CcSEcCtD
Milnacipran—Mediastinal disorder—Capecitabine—esophageal cancer	0.00452	0.00453	CcSEcCtD
Milnacipran—Hypotension—Cisplatin—esophageal cancer	0.00452	0.00452	CcSEcCtD
Milnacipran—Chills—Capecitabine—esophageal cancer	0.0045	0.00451	CcSEcCtD
Milnacipran—Mental disorder—Capecitabine—esophageal cancer	0.00439	0.0044	CcSEcCtD
Milnacipran—Malnutrition—Capecitabine—esophageal cancer	0.00436	0.00437	CcSEcCtD
Milnacipran—Dysuria—Methotrexate—esophageal cancer	0.00436	0.00437	CcSEcCtD
Milnacipran—Neutropenia—Methotrexate—esophageal cancer	0.00436	0.00437	CcSEcCtD
Milnacipran—Paraesthesia—Cisplatin—esophageal cancer	0.00434	0.00435	CcSEcCtD
Milnacipran—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00433	0.00434	CcSEcCtD
Milnacipran—Dyspnoea—Cisplatin—esophageal cancer	0.00431	0.00432	CcSEcCtD
Milnacipran—Flatulence—Capecitabine—esophageal cancer	0.0043	0.00431	CcSEcCtD
Milnacipran—Erectile dysfunction—Methotrexate—esophageal cancer	0.00429	0.0043	CcSEcCtD
Milnacipran—Dysgeusia—Capecitabine—esophageal cancer	0.00427	0.00428	CcSEcCtD
Milnacipran—Decreased appetite—Cisplatin—esophageal cancer	0.0042	0.00421	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00417	0.00418	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.00412	0.00413	CcSEcCtD
Milnacipran—Vision blurred—Capecitabine—esophageal cancer	0.00411	0.00412	CcSEcCtD
Milnacipran—Tremor—Capecitabine—esophageal cancer	0.00409	0.0041	CcSEcCtD
Milnacipran—Haematuria—Methotrexate—esophageal cancer	0.00396	0.00397	CcSEcCtD
Milnacipran—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00393	0.00394	CcSEcCtD
Milnacipran—Syncope—Capecitabine—esophageal cancer	0.00391	0.00392	CcSEcCtD
Milnacipran—Leukopenia—Capecitabine—esophageal cancer	0.00391	0.00391	CcSEcCtD
Milnacipran—Palpitations—Capecitabine—esophageal cancer	0.00386	0.00386	CcSEcCtD
Milnacipran—Loss of consciousness—Capecitabine—esophageal cancer	0.00384	0.00384	CcSEcCtD
Milnacipran—Body temperature increased—Cisplatin—esophageal cancer	0.00382	0.00383	CcSEcCtD
Milnacipran—Hypertension—Capecitabine—esophageal cancer	0.00377	0.00378	CcSEcCtD
Milnacipran—Hepatitis—Methotrexate—esophageal cancer	0.00373	0.00374	CcSEcCtD
Milnacipran—Chest pain—Capecitabine—esophageal cancer	0.00372	0.00372	CcSEcCtD
Milnacipran—Anxiety—Capecitabine—esophageal cancer	0.0037	0.00371	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00369	0.0037	CcSEcCtD
Milnacipran—Urinary tract disorder—Methotrexate—esophageal cancer	0.00369	0.00369	CcSEcCtD
Milnacipran—Urethral disorder—Methotrexate—esophageal cancer	0.00366	0.00367	CcSEcCtD
Milnacipran—Dry mouth—Capecitabine—esophageal cancer	0.00363	0.00364	CcSEcCtD
Milnacipran—Hypersensitivity—Cisplatin—esophageal cancer	0.00356	0.00357	CcSEcCtD
Milnacipran—Infection—Capecitabine—esophageal cancer	0.00354	0.00355	CcSEcCtD
Milnacipran—Erythema multiforme—Methotrexate—esophageal cancer	0.00353	0.00354	CcSEcCtD
Milnacipran—Shock—Capecitabine—esophageal cancer	0.0035	0.00351	CcSEcCtD
Milnacipran—Nervous system disorder—Capecitabine—esophageal cancer	0.00349	0.0035	CcSEcCtD
Milnacipran—Eye disorder—Methotrexate—esophageal cancer	0.00349	0.00349	CcSEcCtD
Milnacipran—Thrombocytopenia—Capecitabine—esophageal cancer	0.00349	0.00349	CcSEcCtD
Milnacipran—Tachycardia—Capecitabine—esophageal cancer	0.00348	0.00348	CcSEcCtD
Milnacipran—Asthenia—Cisplatin—esophageal cancer	0.00347	0.00347	CcSEcCtD
Milnacipran—Cardiac disorder—Methotrexate—esophageal cancer	0.00346	0.00347	CcSEcCtD
Milnacipran—Skin disorder—Capecitabine—esophageal cancer	0.00346	0.00347	CcSEcCtD
Milnacipran—Hyperhidrosis—Capecitabine—esophageal cancer	0.00344	0.00345	CcSEcCtD
Milnacipran—Anorexia—Capecitabine—esophageal cancer	0.0034	0.0034	CcSEcCtD
Milnacipran—Angiopathy—Methotrexate—esophageal cancer	0.00339	0.00339	CcSEcCtD
Milnacipran—Mediastinal disorder—Methotrexate—esophageal cancer	0.00336	0.00337	CcSEcCtD
Milnacipran—Chills—Methotrexate—esophageal cancer	0.00335	0.00336	CcSEcCtD
Milnacipran—Hypotension—Capecitabine—esophageal cancer	0.00333	0.00333	CcSEcCtD
Milnacipran—Diarrhoea—Cisplatin—esophageal cancer	0.00331	0.00331	CcSEcCtD
Milnacipran—Mental disorder—Methotrexate—esophageal cancer	0.00327	0.00328	CcSEcCtD
Milnacipran—Malnutrition—Methotrexate—esophageal cancer	0.00325	0.00326	CcSEcCtD
Milnacipran—Insomnia—Capecitabine—esophageal cancer	0.00322	0.00323	CcSEcCtD
Milnacipran—Paraesthesia—Capecitabine—esophageal cancer	0.0032	0.0032	CcSEcCtD
Milnacipran—Dysgeusia—Methotrexate—esophageal cancer	0.00318	0.00319	CcSEcCtD
Milnacipran—Dyspnoea—Capecitabine—esophageal cancer	0.00318	0.00318	CcSEcCtD
Milnacipran—Dyspepsia—Capecitabine—esophageal cancer	0.00314	0.00314	CcSEcCtD
Milnacipran—Decreased appetite—Capecitabine—esophageal cancer	0.0031	0.0031	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00308	0.00308	CcSEcCtD
Milnacipran—Vomiting—Cisplatin—esophageal cancer	0.00307	0.00308	CcSEcCtD
Milnacipran—Fatigue—Capecitabine—esophageal cancer	0.00307	0.00308	CcSEcCtD
Milnacipran—Vision blurred—Methotrexate—esophageal cancer	0.00306	0.00307	CcSEcCtD
Milnacipran—Rash—Cisplatin—esophageal cancer	0.00305	0.00305	CcSEcCtD
Milnacipran—Constipation—Capecitabine—esophageal cancer	0.00305	0.00305	CcSEcCtD
Milnacipran—Dermatitis—Cisplatin—esophageal cancer	0.00304	0.00305	CcSEcCtD
Milnacipran—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00291	0.00292	CcSEcCtD
Milnacipran—Leukopenia—Methotrexate—esophageal cancer	0.00291	0.00291	CcSEcCtD
Milnacipran—Nausea—Cisplatin—esophageal cancer	0.00287	0.00288	CcSEcCtD
Milnacipran—Urticaria—Capecitabine—esophageal cancer	0.00283	0.00283	CcSEcCtD
Milnacipran—Abdominal pain—Capecitabine—esophageal cancer	0.00282	0.00282	CcSEcCtD
Milnacipran—Body temperature increased—Capecitabine—esophageal cancer	0.00282	0.00282	CcSEcCtD
Milnacipran—Convulsion—Methotrexate—esophageal cancer	0.00282	0.00282	CcSEcCtD
Milnacipran—Chest pain—Methotrexate—esophageal cancer	0.00277	0.00277	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00275	0.00275	CcSEcCtD
Milnacipran—Infection—Methotrexate—esophageal cancer	0.00263	0.00264	CcSEcCtD
Milnacipran—Hypersensitivity—Capecitabine—esophageal cancer	0.00262	0.00263	CcSEcCtD
Milnacipran—Nervous system disorder—Methotrexate—esophageal cancer	0.0026	0.00261	CcSEcCtD
Milnacipran—Thrombocytopenia—Methotrexate—esophageal cancer	0.0026	0.0026	CcSEcCtD
Milnacipran—Skin disorder—Methotrexate—esophageal cancer	0.00258	0.00258	CcSEcCtD
Milnacipran—Hyperhidrosis—Methotrexate—esophageal cancer	0.00256	0.00257	CcSEcCtD
Milnacipran—Asthenia—Capecitabine—esophageal cancer	0.00256	0.00256	CcSEcCtD
Milnacipran—Anorexia—Methotrexate—esophageal cancer	0.00253	0.00253	CcSEcCtD
Milnacipran—Pruritus—Capecitabine—esophageal cancer	0.00252	0.00252	CcSEcCtD
Milnacipran—Hypotension—Methotrexate—esophageal cancer	0.00248	0.00248	CcSEcCtD
Milnacipran—Diarrhoea—Capecitabine—esophageal cancer	0.00244	0.00244	CcSEcCtD
Milnacipran—Insomnia—Methotrexate—esophageal cancer	0.0024	0.0024	CcSEcCtD
Milnacipran—Paraesthesia—Methotrexate—esophageal cancer	0.00238	0.00239	CcSEcCtD
Milnacipran—Dyspnoea—Methotrexate—esophageal cancer	0.00236	0.00237	CcSEcCtD
Milnacipran—Somnolence—Methotrexate—esophageal cancer	0.00236	0.00236	CcSEcCtD
Milnacipran—Dizziness—Capecitabine—esophageal cancer	0.00236	0.00236	CcSEcCtD
Milnacipran—Dyspepsia—Methotrexate—esophageal cancer	0.00233	0.00234	CcSEcCtD
Milnacipran—Decreased appetite—Methotrexate—esophageal cancer	0.00231	0.00231	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00229	0.00229	CcSEcCtD
Milnacipran—Fatigue—Methotrexate—esophageal cancer	0.00229	0.00229	CcSEcCtD
Milnacipran—Vomiting—Capecitabine—esophageal cancer	0.00226	0.00227	CcSEcCtD
Milnacipran—Rash—Capecitabine—esophageal cancer	0.00225	0.00225	CcSEcCtD
Milnacipran—Dermatitis—Capecitabine—esophageal cancer	0.00224	0.00225	CcSEcCtD
Milnacipran—Headache—Capecitabine—esophageal cancer	0.00223	0.00224	CcSEcCtD
Milnacipran—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00217	0.00217	CcSEcCtD
Milnacipran—Nausea—Capecitabine—esophageal cancer	0.00212	0.00212	CcSEcCtD
Milnacipran—Urticaria—Methotrexate—esophageal cancer	0.00211	0.00211	CcSEcCtD
Milnacipran—Body temperature increased—Methotrexate—esophageal cancer	0.0021	0.0021	CcSEcCtD
Milnacipran—Abdominal pain—Methotrexate—esophageal cancer	0.0021	0.0021	CcSEcCtD
Milnacipran—Hypersensitivity—Methotrexate—esophageal cancer	0.00195	0.00196	CcSEcCtD
Milnacipran—Asthenia—Methotrexate—esophageal cancer	0.0019	0.00191	CcSEcCtD
Milnacipran—Pruritus—Methotrexate—esophageal cancer	0.00188	0.00188	CcSEcCtD
Milnacipran—Levomilnacipran—ABCB1—esophageal cancer	0.00184	1	CrCbGaD
Milnacipran—Diarrhoea—Methotrexate—esophageal cancer	0.00181	0.00182	CcSEcCtD
Milnacipran—Dizziness—Methotrexate—esophageal cancer	0.00175	0.00176	CcSEcCtD
Milnacipran—Vomiting—Methotrexate—esophageal cancer	0.00169	0.00169	CcSEcCtD
Milnacipran—Rash—Methotrexate—esophageal cancer	0.00167	0.00168	CcSEcCtD
Milnacipran—Dermatitis—Methotrexate—esophageal cancer	0.00167	0.00167	CcSEcCtD
Milnacipran—Headache—Methotrexate—esophageal cancer	0.00166	0.00166	CcSEcCtD
Milnacipran—Nausea—Methotrexate—esophageal cancer	0.00158	0.00158	CcSEcCtD
